Anti-Hypertensive Drugs - Chad

Chad

The Anti-Hypertensive Drugs market in Chad is expected to achieve a revenue of US$0.74m in 2024.
Furthermore, a steady annual growth rate (CAGR 2024-2029) of -0.55% is anticipated, leading to a market volume of US$0.72m by 2029.
When compared globally, United States is projected to generate the highest revenue of US$12,290.00m in 2024.
Chad's market for anti-hypertensive drugs is rapidly growing due to the high prevalence of hypertension in the country.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Chad has seen a steady growth in recent years.

Customer preferences: In Chad, the demand for Anti-Hypertensive Drugs has been increasing due to the rising prevalence of hypertension. The population over the age of 40 is particularly affected, and this group is expected to grow in the coming years. Patients are looking for effective and affordable drugs to manage their condition.

Trends in the market: The Anti-Hypertensive Drugs market in Chad is dominated by imported drugs. The market is highly competitive, with several multinational pharmaceutical companies operating in the country. The market is expected to continue to grow, driven by the increasing prevalence of hypertension and the availability of affordable drugs.

Local special circumstances: Chad is a low-income country, and access to healthcare is limited. The country faces several challenges, including a shortage of healthcare workers, inadequate infrastructure, and limited financial resources. These challenges have an impact on the availability and affordability of Anti-Hypertensive Drugs.

Underlying macroeconomic factors: Chad's economy is heavily dependent on oil exports, which account for over 90% of the country's export revenue. The country has been hit hard by the decline in oil prices in recent years, which has had a negative impact on the healthcare sector. The government has limited resources to invest in healthcare, and this has affected the availability and affordability of drugs, including Anti-Hypertensive Drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.